Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pardes Biosciences
Biotech
Pardes changes hands (sort of) in wake of COVID-19 trial fail
Months after Pardes Biosciences' COVID-19 antiviral flunked in phase 2, the biotech has been bailed out via an acquisition by its key shareholders.
James Waldron
Jul 17, 2023 9:25am
Pardes plans descent from COVID-19 antiviral flight path
Apr 3, 2023 10:25am
Merck chief patient officer leaving for NIH—Chutes & Ladders
Mar 4, 2022 9:30am
Pardes snags ex-Dermira CEO Wiggans to lead COVID-19 antiviral
Mar 3, 2022 2:00pm
